168 related articles for article (PubMed ID: 37931634)
1. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH; Barratt J; Heerspink HJL; Alpers CE; Bieler S; Chae DW; Diva UA; Floege J; Gesualdo L; Inrig JK; Kohan DE; Komers R; Kooienga LA; Lafayette R; Maes B; Małecki R; Mercer A; Noronha IL; Oh SW; Peh CA; Praga M; Preciado P; Radhakrishnan J; Rheault MN; Rote WE; Tang SCW; Tesar V; Trachtman H; Trimarchi H; Tumlin JA; Wong MG; Perkovic V;
Lancet; 2023 Dec; 402(10417):2077-2090. PubMed ID: 37931634
[TBL] [Abstract][Full Text] [Related]
2. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL; Radhakrishnan J; Alpers CE; Barratt J; Bieler S; Diva U; Inrig J; Komers R; Mercer A; Noronha IL; Rheault MN; Rote W; Rovin B; Trachtman H; Trimarchi H; Wong MG; Perkovic V;
Lancet; 2023 May; 401(10388):1584-1594. PubMed ID: 37015244
[TBL] [Abstract][Full Text] [Related]
3. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN; Alpers CE; Barratt J; Bieler S; Canetta P; Chae DW; Coppock G; Diva U; Gesualdo L; Heerspink HJL; Inrig JK; Kirsztajn GM; Kohan D; Komers R; Kooienga LA; Lieberman K; Mercer A; Noronha IL; Perkovic V; Radhakrishnan J; Rote W; Rovin B; Tesar V; Trimarchi H; Tumlin J; Wong MG; Trachtman H;
N Engl J Med; 2023 Dec; 389(26):2436-2445. PubMed ID: 37921461
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R; Kristensen J; Stone A; Floege J; Tesař V; Trimarchi H; Zhang H; Eren N; Paliege A; Reich HN; Rovin BH; Barratt J;
Lancet; 2023 Sep; 402(10405):859-870. PubMed ID: 37591292
[TBL] [Abstract][Full Text] [Related]
5. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
Trachtman H; Nelson P; Adler S; Campbell KN; Chaudhuri A; Derebail VK; Gambaro G; Gesualdo L; Gipson DS; Hogan J; Lieberman K; Marder B; Meyers KE; Mustafa E; Radhakrishnan J; Srivastava T; Stepanians M; Tesar V; Zhdanova O; Komers R;
J Am Soc Nephrol; 2018 Nov; 29(11):2745-2754. PubMed ID: 30361325
[TBL] [Abstract][Full Text] [Related]
6. Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety.
Campbell KN; Gesualdo L; Murphy E; Rheault MN; Srivastava T; Tesar V; Komers R; Trachtman H
Kidney Med; 2024 Jun; 6(6):100833. PubMed ID: 38831932
[TBL] [Abstract][Full Text] [Related]
7. IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.
Barratt J; Rovin B; Wong MG; Alpers CE; Bieler S; He P; Inrig J; Komers R; Heerspink HJL; Mercer A; Noronha IL; Radhakrishnan J; Rheault MN; Rote W; Trachtman H; Trimarchi H; Perkovic V;
Kidney Int Rep; 2023 May; 8(5):1043-1056. PubMed ID: 37180506
[TBL] [Abstract][Full Text] [Related]
8. Sparsentan: A First-in-Class Dual Endothelin and Angiotensin II Receptor Antagonist.
Chiu AW; Bredenkamp N
Ann Pharmacother; 2024 Jun; 58(6):645-656. PubMed ID: 37706310
[TBL] [Abstract][Full Text] [Related]
9. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC; Barratt J; Cook H; Coppo R; Feehally J; de Fijter JW; Floege J; Hetzel G; Jardine AG; Locatelli F; Maes BD; Mercer A; Ortiz F; Praga M; Sørensen SS; Tesar V; Del Vecchio L;
Lancet; 2017 May; 389(10084):2117-2127. PubMed ID: 28363480
[TBL] [Abstract][Full Text] [Related]
10. Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy.
Trachtman H; Komers R; Inrig J
Expert Rev Clin Immunol; 2024 Jun; 20(6):571-576. PubMed ID: 38362830
[TBL] [Abstract][Full Text] [Related]
11. Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis.
Komers R; Diva U; Inrig JK; Loewen A; Trachtman H; Rote WE
Kidney Int Rep; 2020 Apr; 5(4):494-502. PubMed ID: 32274453
[TBL] [Abstract][Full Text] [Related]
12. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
13. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
Knoll GA; Fergusson D; Chassé M; Hebert P; Wells G; Tibbles LA; Treleaven D; Holland D; White C; Muirhead N; Cantarovich M; Paquet M; Kiberd B; Gourishankar S; Shapiro J; Prasad R; Cole E; Pilmore H; Cronin V; Hogan D; Ramsay T; Gill J
Lancet Diabetes Endocrinol; 2016 Apr; 4(4):318-26. PubMed ID: 26608067
[TBL] [Abstract][Full Text] [Related]
14. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
15. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
16. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study.
Yu MY; Kim YC; Koo HS; Chin HJ
PLoS One; 2017; 12(11):e0188375. PubMed ID: 29155873
[TBL] [Abstract][Full Text] [Related]
17. Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.
Mohebbi N; Ritter A; Wiegand A; Graf N; Dahdal S; Sidler D; Arampatzis S; Hadaya K; Mueller TF; Wagner CA; Wüthrich RP
Lancet; 2023 Feb; 401(10376):557-567. PubMed ID: 36708734
[TBL] [Abstract][Full Text] [Related]
18. Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice.
Campbell KN; Griffin S; Trachtman H; Geletka R; Wong MG
Int J Nephrol Renovasc Dis; 2023; 16():281-291. PubMed ID: 38149041
[TBL] [Abstract][Full Text] [Related]
19. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Liu LJ; Yang YZ; Shi SF; Bao YF; Yang C; Zhu SN; Sui GL; Chen YQ; Lv JC; Zhang H
Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
[TBL] [Abstract][Full Text] [Related]
20. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL; Parving HH; Andress DL; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Melnick JZ; Miller MG; Pergola PE; Perkovic V; Tobe S; Yi T; Wigderson M; de Zeeuw D;
Lancet; 2019 May; 393(10184):1937-1947. PubMed ID: 30995972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
